Wird geladen...
Initial rivaroxaban dosing in patients with atrial fibrillation
BACKGROUND: Rivaroxaban is a non‐vitamin K oral anticoagulant and has been approved for prevention of stroke and systemic embolism in patients with non‐valvular atrial fibrillation (AF). Current labeling recommends 20 mg once a day (q.d.) as a standard dose and a reduced dose of 15 mg q.d. in patien...
Gespeichert in:
| Veröffentlicht in: | Clin Cardiol |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Wiley Periodicals, Inc.
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6788464/ https://ncbi.nlm.nih.gov/pubmed/31317562 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.23235 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|